SciELO - Scientific Electronic Library Online

 
vol.21 número4Epidemiología de los envenenamientos por animales acuáticos reportados a un centro de control toxicológico colombianoNeurociencia y ejercicio: un indicador de salud y aprendizaje en el contexto educativo índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista de Salud Pública

versión impresa ISSN 0124-0064

Resumen

ARANDA, Monica B.  y  SABALETTE, Karina B.. Biological cancer therapies: an approach towards accessibility. Rev. salud pública [online]. 2019, vol.21, n.4, pp.462-468.  Epub 11-Ago-2020. ISSN 0124-0064.  https://doi.org/10.15446/rsap.v21n4.73686.

Monoclonal antibodies are a useful tool for laboratory diagnosis and an instrument used in the treatment of various diseases and represent one of the most important groups of new drugs for the treatment of cancer. The revolution in the world occured in 1975 when Milstein and Köhler discovered monoclonal antibodies in Cambridge.

Objective

To review the use of monoclonal antibodies in medicine and in the treatment of cancer. To provide a generalized vision of the concept of monoclonal antibody to explain its therapeutic applicability, and to approach an economic, health-care approach to obtaining and accessing new therapies.

Method

In the characterization of the research phenomenon, the descriptive study, the collection of documentary data and the correlation between the different sources were used.

Discussion

However, the costs for both the patient and the public health systems are still high, and the cost-effectiveness assessment must be optimized so that cost-effectiveness and access to time for patients can be compatible. And the challenge of developing new mAbs aimed at new targets, improving the safety profile, avoiding, or reducing adverse immune reactions and achieving lower production costs through improvements in biotechnology, is left open.

Palabras clave : Biological therapy; antibodies; monoclonal; biosimilar pharmaceuticals (source: MeSH, NLM).

        · resumen en Español     · texto en Español     · Español ( pdf )